"Systemic JIA is likely best classified as an autoinflammatory disease, based upon the robust clinical response to IL-1 inhibition and the absence of known autoantibodies, autoreactive T-cells, or association with HLA genotypes," explained Timothy Beukelman, MD, of the University of Alabama at Birmingham, who was a co-author of the updated ACR guidelines.